News

Lumanity announces strategic partnership with HealthVerity to provide streamlined access to real-world data, world-class analytics, and value demonstration expertise

Lumanity announces strategic partnership with HealthVerity to provide streamlined access to real-world data, world-class analytics, and value demonstration expertise 1200 628 Doug DeMarra

Lumanity announces strategic partnership with HealthVerity to provide streamlined access to real-world data, world-class analytics, and value demonstration expertise

NOVEMBER 28, 2022

Lumanity’s deep data analytics, value demonstration, and therapeutic area expertise alongside HealthVerity’s patient identity resolution technology and leading ecosystem of interoperable real-world data enables evidence generation across the pharma lifecycle.

NEW YORK, NY — Lumanity and HealthVerity today announced a strategic partnership that will enable life sciences companies to derive better outcomes from the HealthVerity IPGE platform, including the nation’s largest, fully-interoperable healthcare and consumer data ecosystem, in combination with Lumanity’s world-class data and real-world evidence (RWE) generation expertise. The partnership creates tremendous value for clients seeking to leverage Lumanity’s unique ability to identify the optimal, research-ready real-world data (RWD) to support real-world research, as well as its strengths in global health economics and outcomes research (HEOR), safety, and data analytics.

“We are thrilled to partner with HealthVerity as part of the launch of our global RWE practice,” said Gema Parlange, Chief Commercial and Development Officer and the Global Practice Lead for RWE at Lumanity. “We are very impressed with the depth and breadth of the HealthVerity IPGE platform, including its highly accurate patient identity resolution technology and broad ecosystem of data partners, and are excited about the possibilities of bringing multi-source, cohort-specificity together with our deep domain expertise in HEOR and Value Demonstration. We look forward to working together to provide innovative new solutions for our clients and partners.”

The HealthVerity IPGE platform is an integrated technology and RWD infrastructure based on four foundational elements, Identity, Privacy, Governance, and Exchange, that allow disparate data to be accurately resolved to unique but persistent identities, linked, and exchanged in a privacy-protected manner for a myriad of use cases. The HealthVerity RWD ecosystem supports a comprehensive array of customer use cases that leverage the convergence of medical claims data, lab data and results, pharmacy data, EMR data, hospital chargemaster data, and social determinants of health data.

“This partnership combines our 10x accuracy advantage in patient identity resolution, access to novel data assets, and Lumanity’s deep domain expertise in HEOR, value demonstration, patient-reported outcomes, and media strategy,” said Sandy Leonard, Senior Vice President of Partnerships and RWD Solutions at HealthVerity. “We believe this is a powerful combination to help our customers build more complete and accurate patient journeys to support their most pressing research and analytics projects.”

Lumanity was formed by bringing together the expertise and capabilities of several exceptional organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, Innovative Edge, Endpoint Outcomes, and Clarion. The partnership with HealthVerity comes on the heels of launching Lumanity’s Real World Evidence global practice, and further enhances Lumanity’s unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject matter experts, and proven problem solvers with advanced clinical, scientific, and real-world data capabilities.

About Lumanity

Lumanity applies incisive thinking and decisive action to cut through complex situations and deliver transformative outcomes to accelerate and optimize access to medical advances. By transforming data and information into real-world insights and evidence, Lumanity powers successful commercialization and empowers patients, providers, payers, and regulators to take timely and decisive action. With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, its 1,300+ experts work with nearly all the top pharmaceutical and more than 100 biotech companies around the world. Turning aspiration into reality, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of 80 brands and new indications, and numerous award-winning product campaigns every year. For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Lumanity
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com

HealthVerity
Colleen Stoker
cstoker@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

HealthVerity achieves FedRAMP authorized designation

HealthVerity achieves FedRAMP authorized designation 2400 1256 Doug DeMarra

HealthVerity achieves FedRAMP authorized designation

OCTOBER 25, 2022

Privacy-preserving record linkage solution receives FedRAMP authorization, allowing federal agencies to securely and privately link healthcare data.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance and Exchange (IPGE) for real-world data, today announced that it has achieved Federal Risk and Authorization Management Program (FedRAMP) authorization at the Moderate security impact level for its Privacy-Preserving Record Linkage (PPRL) solution. At present, the FedRAMP marketplace lists 40 federal agencies that have granted HealthVerity an Authority to Operate (ATO).

HealthVerity PPRL leverages advanced identity resolution techniques to link patient records across time and data sources by creating unique but persistent identities, also called HealthVerity IDs (HVIDs). HVIDs can be used to source and study patient-centric transactions in a HIPAA-compliant manner at scale from the nation’s largest ecosystem of healthcare and consumer data. Now listed on the FedRAMP Marketplace, the HealthVerity PPRL solution can be contracted by any government agency without additional vetting required — eliminating onboarding cost and time burdens.

FedRAMP is a federal government program that promotes and provides a standardized approach to security assessment, authorization, and continuous monitoring for cloud-based information system products and services. It uses a common, standardized security framework to assess cloud products and services to ensure the cloud service provider’s (CSP’s) product and the organization’s security complies with required security standards for the protection of federal information.

“Obtaining FedRAMP certification for HealthVerity PPRL allows federal government agencies to benefit from the industry’s most accurate means to manage identity and linkage for healthcare and consumer data on a fully interoperable, privacy-protected basis,” said John Cappiello, chief technology officer for HealthVerity. “With a FedRAMP Moderate ATO, HealthVerity joins a very distinguished and select group of CSPs delivering the highest security standards in the healthcare industry.”

HealthVerity has a history of serving key government agencies to support public health initiatives. Last month, HealthVerity was awarded a contract with the National Cancer Institute (NCI) to implement a data discovery and governance platform for their National Childhood Cancer Registry (NCCR). Additionally, HealthVerity was awarded the largest-ever contract for real-world data by the Centers for Disease Control and Prevention (CDC) in September 2021 to advance COVID-19 research. The organization also supported the NCI in a groundbreaking study of SARS-CoV-2 antibodies in February 2021, announced a research contract with the U.S. Food and Drug Administration (FDA) to support a COVID-19 clinical study and treatment opportunities in June 2020, and was awarded a PPRL contract for COVID-19 vaccine data with the Department of Health and Human Services (HHS) in November 2020.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

Labcorp enhances clinical trial and drug development capabilities through real-world data collaboration with HealthVerity

Labcorp enhances clinical trial and drug development capabilities through real-world data collaboration with HealthVerity 150 150 Doug DeMarra

Labcorp enhances clinical trial and drug development capabilities through real-world data collaboration with HealthVerity

JUNE 21, 2022 — 08:30 AM EDT

BURLINGTON, NC — (Business Newswire) — Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs.

HealthVerity’s IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.’s largest ecosystem1 of health care and consumer data.

“This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications,” said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. “By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines.”

Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity’s RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp’s ability to be a trusted source of information for its clients.

“Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data,” said Andrew Kress, CEO of HealthVerity. “Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client’s applications of choice.”

Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.

View the full release here: https://www.businesswire.com/news/home/20220620005641/en/

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com

1 Internal data from HealthVerity

2 Internal data from HealthVerity

Labcorp Contacts

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

HealthVerity Media Contact

Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets 150 150 Doug DeMarra

ASCO’s CancerLinQ and HealthVerity collaborate to accelerate cancer research by linking real-world datasets

JUNE 08, 2022 — 08:30 AM EDT

The collaboration aims to fulfill a shared vision of improving cancer care and research by connecting disparate real-world data to generate deeper insights into unique cancer journeys.

ALEXANDRIA, VA — (ASCO) — CancerLinQ® LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, and HealthVerity, Inc., today announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration leverages HealthVerity’s Privacy-Preserving Record Linkage (PPRL) technology to make CancerLinQ oncology data fully interoperable with de-identified patient data from the nation’s largest ecosystem of healthcare and consumer data providers. Qualified researchers will now have the ability to explore longitudinal patient journeys across a multitude of data types that better reveal the context around the origin, progression, treatment, and outcomes for a full breadth of cancer diagnoses.

With only 5 percent of patients with cancer participating in clinical trials, the use of real-world oncology data in research can help expand the pool of knowledge from which researchers can learn. CancerLinQ and HealthVerity allow researchers to learn from all patients with cancer – not only those enrolled in clinical trials–by providing access to broadscale, patient-longitudinal, real-world data that can provide researchers with a more comprehensive view of unique patient journeys.

“CancerLinQ is driven by its goal of improving the care of every single patient with cancer,” said Sean Khozin, MD, MPH, chief executive officer (CEO) of CancerLinQ. “To that end, this new collaboration helps us bring together disparate data-sets that capture the longitudinal experience of patients with cancer, giving us the ability to unlock insights that inform high-quality, equitable patient care and research.”

“We are thrilled to be working alongside CancerLinQ to offer researchers a more comprehensive way to study the complex journeys of cancer patients,” said Andrew Kress, CEO of HealthVerity. “By leveraging the HealthVerity IPGE platform to connect real-world datasets in a HIPAA-compliant and privacy protected manner, we are creating an incredible opportunity for public health and government agencies to make the discoveries that could one day lead to cures for most forms of cancer.”

CancerLinQ has one of the largest and most-diverse real-world-oncology databases that include de-identified data from more than six million patients with cancer and benign hematological conditions from all 50 states. The CancerLinQ network is a growing ecosystem of over 100 cancer centers and community oncology practices.

The HealthVerity IPGE platform is an integrated technology and real-world data infrastructure platform based on four foundational elements—identity, privacy, governance, and exchange—which allow disparate data to be accurately resolved to unique privacy-protected identities, linked, and exchanged for a myriad of use cases.

To learn more about the collaboration and how you can access one of the nation’s largest interoperable de-identified real-world oncology data ecosystem, visit CancerLinQ.org.

View the full release here: https://www.asco.org/about-asco/press-center/news-releases/cancerlinq-and-healthverity-collaborate-linking-datasets

About ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.

About CancerLinQ

CancerLinQ® is a real-world oncology data platform developed by ASCO that collects and aggregates longitudinal EHR data from oncology practices throughout the United States. CancerLinQ improves the quality of patient care and accelerates discovery by securely compiling, harmonizing, analyzing, and de-identifying vast amounts of information on patient characteristics (e.g., molecular profiles, comorbidities), treatments, and long-term side effects. By using data from over six million patients in near real time, CancerLinQ can identify trends and associations between myriad variables, thereby enabling physicians to generate new hypotheses and apply those conclusions to improve care in real-world settings. To learn more about collaborations, visit Collaborations | ASCO CancerLinQ.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry 150 150 Doug DeMarra

Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry

APRIL 27, 2022 — 08:30 AM EDT

Ipsos MMA brings a new approach to measuring the impact of commercial investments across the patient and physician journey to maximize the value of campaigns for Pharma brands and their agency partners.

NEW YORK, NY — (PRNewswire) — Ipsos MMA, a leader in helping pharma and healthcare brands measure and optimize the value of their patient and HCP promotions, today announced a partnership that integrates Ipsos MMA’s Unified Patient & HCP Attribution model with HealthVerity IPGE, the industry’s leading infrastructure for patient identity resolution, privacy, governance and exchange of broadscale healthcare and consumer data. The partnership delivers privacy-protected and HIPAA-compliant activations with media platforms for pharmaceutical brands as an end-to-end, closed-loop measurement and optimization solution.

This innovative and future-proofed capability enables pharmaceutical marketers to generate and activate audiences, measure the quality of the audiences reached and optimize omnichannel net conversion lift while campaigns are in market. Through a combination of privacy-protected, HIPAA-compliant data, processes and advanced AI modeling, brands can now automate “next best actions” across patient and physician journeys to drive incremental scripts and adherence, maximizing long-term profits.

Ipsos MMA’s Unified Patient & HCP Attribution model has been validated with clients and has been shown to produce measurable improvements in revenue and profits. Ipsos MMA has also been named a leader in The Forrester Wave™ : Marketing Measurement & Optimization Solutions, Q1 2022.

“We have partnered with some of the top pharma brands, their agencies, HealthVerity and industry data partners/platforms across the media ecosystem to validate that our integrated solutions will produce better results for our clients. We believe that by working closely with them to operationalize these capabilities it will prove to provide transformational results for the industry,” said Doug Brooks, EVP at Ipsos MMA. “Ipsos MMA’s Unified Patient & HCP Attribution capability unlocks the omnichannel opportunity for pharma executives by taking advantage of synergies between DTC, HCP and sales force, enabling orchestrated planning, optimizing campaigns in-market, targeting and creating new audiences and leveraging both Patient and Physician journeys for Next Best Action through an innovative use of AI.”

“With this capability, pharma brands can integrate patient and HCP marketing journeys and enhanced data attributes to generate, activate, and prioritize high-value audiences that are linked to downstream conversions while campaigns are live. Our unique solution does not rely on third-party cookies and is not impacted by advancements in data deprecation. This approach gives brand and media planners true cross-platform and omnichannel investment optimization opportunities. In a world where data privacy is critical, we can offer marketers and their agencies a safe way to activate and measure both traditional and digital channels against intended audiences,” said Robert Cardarelli, EVP Analytics and Attribution for Ipsos MMA.

What is the benefit of this approach to Pharmaceutical Marketers?

Holistic Measurement and Campaign Management
Omnichannel impact of Patient and Physician journeys to increase patient visitation, NBRx and adherence

Multi-channel Optimization
Optimize campaigns across audiences, targeting tactics, partners, creative measures and reach & frequency – while in-flight

Sequencing
Identify which Next Best Actions need to be taken across both Patient and Physician journeys to drive maximum conversion lift and ROI

Campaign Performance Management
Ensure optimal audience quality and cost per qualified audience while meeting targeting benchmarks and downstream end actions

Interoperable Data Ecosystem
With over 150 billion de-identified transactions from more than 75 unique data sources and 330 million patients, HealthVerity provides access to the largest healthcare and consumer data ecosystem available in the market today.

HIPAA-Compliant Data Clean Rooms
Securely brings together data with a HIPAA-compliant data clean room for audience selection and media measurement for back-end analytics from HealthVerity. The complete solution enables a full closed-loop process to help target and optimize campaigns while ensuring clients get the desired outcomes.

Learn more about Ipsos MMA’s Unified Patient/HCP Attribution capability.

View the full release here: https://www.prnewswire.com/news-releases/ipsos-mma-and-healthverity-partner-to-reinvent-omnichannel-patient-and-hcp-attribution-in-the-pharma-industry-301534210.html

About Ipsos MMA

Ipsos MMA is a leading global analytics consultancy founded in 1989. The company enables its clients to achieve higher revenues and operating profits via their forward-looking, data-driven analytics, software and consulting solutions. Ipsos MMA is headquartered in New York, NY and is a part of the leading global custom market research company Ipsos, which has major offices in over 80 locations worldwide. To learn more about Ipsos MMA, visit mma.com.

About HealthVerity

Pharmaceutical manufacturers, payers and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance and Exchange, enables the discovery of RWD across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about out how HealthVerity and Ipsos MMA work together visit our Partners Page.

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research 150 150 Doug DeMarra

HealthVerity launches MOM, the Maternal Outcomes Masterset, to advance pregnancy health research

APRIL 26, 2022

MOM delivers the pre-eminent approach to understanding clinical attributes that best answer the industry’s most challenging maternal health questions, including recent increases in maternal mortality and morbidity in the U.S.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced the launch of MOM, the Maternal Outcomes Masterset, a groundbreaking approach for generating novel insights around the impact of healthcare interventions for pregnant women and their babies. By accurately linking de-identified healthcare records of over 1.6 million pregnant women to their newborns, HealthVerity delivers a more comprehensive way for clinical researchers to study the patient journey from pre-pregnancy to birth and beyond, all in a HIPAA-compliant and privacy protected manner.

MOM was created to address a long-standing challenge for the healthcare industry, the lack of reliable evidence on drug safety during pregnancy. The COVID-19 pandemic highlighted this gap when patients and providers were faced with minimal data and uncertain guidance on whether expectant mothers should be vaccinated. The evidence gap exists largely due to the exclusion of pregnant women from clinical trials, as well as the scarcity of relevant retrospective data sources and pregnancy registries. According to draft guidance from the U.S. Food and Drug Administration, “pregnancy registry data is not sufficient to assess the safety of products during pregnancy. Other methods are needed to corroborate registry findings.” Furthermore, with the rate of maternal mortality climbing 18% in 2020, according to a new report by the Centers for Disease Control and Prevention (CDC), the Biden-Harris Administration has recently committed to a proposed maternity care quality hospital designation.

“In the Spring of 2020, as we were building a real-world evidence system for biopharma manufacturers and regulators to assess treatment approaches for COVID-19, it became clear to us that the market had very few reliable options to study the maternal journey, ” said Sandy Leonard, Senior Vice President of Partnerships and Real-World Data for HealthVerity. “We then began a year-long process that leveraged the HealthVerity IPGE platform to uniquely solve for the complex challenges of integrating broad-based clinical data on both mother and infant while also meeting the complex privacy requirements of HIPAA.”

Adoption of MOM among the clinical research community is advancing quickly, with SK Life Sciences and the CDC among a growing list of clients leveraging the masterset to advance maternal health outcomes research.

“We were looking for a better way to capture the full maternal health journey of pregnant women using anti-seizure medication”, said Sean Stern, Director of Health Economics and Outcomes Research for SK Life Sciences. “Through MOM, we’re able to crosswalk medical claims and pharmacy data for mom and baby, allowing us to see the relationship between mom and baby and gain more visibility into pregnancy health outcomes.”

MOM is unique in its ability to accurately household de-identified healthcare records of more than 1.6 million pregnant women with their newborns by leveraging key data sources within the nation’s largest ecosystem for healthcare data. Patient cohorts can be easily designated by researchers to explore key patient interactions, health equity and many more long-term objectives.

Key attributes that only MOM can deliver:

Purpose-built for pregnancy studies
MOM was designed to enable researchers to use longitudinal clinical data to follow mothers and their babies in tandem throughout their pregnancy journey, and beyond. The mom-baby linked data preserves critical data elements such as race, ethnicity, maternal age, birth events and pregnancy outcomes to enable novel pregnancy studies.

Regulatory quality, HIPAA-compliant, and research-ready
HealthVerity has solved a complex industry challenge of linking mom and baby data in a way that maintains the most critical data elements for pregnancy-related research while also meeting the most exacting standards of HIPAA. Because MOM is covered under HealthVerity’s third party expert determination, clients can begin data analytics work on day one.

Commercial and Medicaid data for more detailed analyses
MOM is sourced from over 150 U.S. healthcare payers, including both Commercial and Medicaid payers. Currently comprised of medical claims, pharmacy claims, enrollment data and lab results from the nation’s largest real-world data ecosystem, MOM enables access to more than five years of retrospective data, as well as prospective data options leveraging HealthVerity’s persistent identity resolution technology. EMR and hospital chargemaster data will be added in the months ahead.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

The Missing Link – Solving patient privacy protection and data linkage challenges for the National Public Health Data System

The Missing Link – Solving patient privacy protection and data linkage challenges for the National Public Health Data System 150 150 Doug DeMarra

FedHealthIT

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors 150 150 Doug DeMarra

HealthVerity appoints Michael J. Cavanagh and Dr. Raquel Bono to its Board of Directors

FEBRUARY 24, 2022

Cavanagh and Bono bring exceptional experience in healthcare, financial and strategic management for market-leading organizations.

PHILADELPHIA, PA — (PRNewswire) — HealthVerity, Inc., the leader in Identity, Privacy, Governance and Exchange (IPGE) for real-world data, today announced that Michael J. Cavanagh, President and Chief Financial Officer of Comcast Corporation, and Dr. Raquel Bono, Chief Health Officer of Viking, have been appointed to its board of directors.

Cavanagh brings decades of exceptional expertise in guiding high growth businesses to the HealthVerity board.  In his role at Comcast Corporation, he has a broad range of responsibilities, including overseeing all financial functions, corporate development, strategic planning, and corporate administration. Cavanagh joined Comcast in 2015 after spending more than 20 years in the financial services industry at companies like JPMorgan Chase and The Carlyle Group.

A board-certified trauma surgeon and retired Vice Admiral of the United States Navy Medical Corps, Dr. Bono most recently led Washington State’s medical and healthcare systems response to the COVID-19 pandemic.  She saw duty in Operations Desert Shield and Desert Storm and is the first female Navy medical officer to have achieved three-star rank. As CEO and Director for the Defense Health Agency (DHA), Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel.

Mike Cavanagh is one of the most accomplished strategic financial leaders in corporate America and will bring strong capital markets and corporate governance expertise to the company,” said Andrew Kress, CEO of HealthVerity. “His participation on the Board will significantly enhance the value that we offer to our Pharmaceutical Manufacturer, Insurance and Government clients.”

“Dr. Bono’s decorated military service, broad organizational leadership and unique healthcare insights will be a tremendous asset to the company and we are honored to welcome her to the Board,” said Kress. “Her experience and counsel will be critical as we enter the next phase of our journey to bring critical infrastructure to the healthcare insights economy.”

Cavanagh earned a B.A. from Yale University and a J.D. from the University of Chicago. He serves on the Board of Trustees of Yale and is Chairman of its Investment Committee. Cavanagh is also a member of the Council on Foreign Relations.

Dr. Bono earned a B.A. from the University of Texas at Austin and M.D. from the School of Medicine at the Texas Tech University Health Sciences Center. She also holds an MBA from the Carson College of Business at Washington State University, is a Diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons and a Senior Fellow with the Johns Hopkins University Applied Physics Laboratory. Her personal decorations include a Defense Distinguished Service Medal, three Defense Superior Service Medals, three Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation Medals.

“I am excited to be joining the HealthVerity Board at such an important moment in the company’s growth and believe that the organization is well positioned to continue to help its clients recognize the best return on investment in their data strategies,” said Cavanagh.

“I am delighted to join the HealthVerity team and look forward to contributing to the company’s technological approach to solving some of the most difficult challenges in healthcare,” said Dr. Bono.

With these appointments, Cavanagh and Bono will complement HealthVerity’s seasoned management team, an experienced board of directors and accomplished founders with extensive experience across healthcare and technology.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Jen Kaczmarczyk
Vice President of Marketing
jkaczmarczyk@healthverity.com

REQUEST DEMO

HealthVerity IPGE is your answer for Identity, Privacy, Governance and Exchange.

To explore the power of the HealthVerity IPGE platform, fill out the form with your contact information.

13 Greater Philadelphia Startups to Watch in 2022

13 Greater Philadelphia Startups to Watch in 2022 150 150 Doug DeMarra

PHL INNO